Cargando…

Variation in transcriptional regulation of cyclin dependent kinase inhibitor p21(waf1/cip1 )among human bronchogenic carcinomas

BACKGROUND: Cell proliferation control depends in part on the carefully ordered regulation of transcription factors. The p53 homolog p73, contributes to this control by directly upregulating the cyclin dependent kinase inhibitor, p21(waf1/cip1). E2F1, an inducer of cell proliferation, directly upreg...

Descripción completa

Detalles Bibliográficos
Autores principales: Harr, Michael W, Graves, Timothy G, Crawford, Erin L, Warner, Kristy A, Reed, Cheryl AM, Willey, James C
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1185562/
https://www.ncbi.nlm.nih.gov/pubmed/16014176
http://dx.doi.org/10.1186/1476-4598-4-23
_version_ 1782124741695373312
author Harr, Michael W
Graves, Timothy G
Crawford, Erin L
Warner, Kristy A
Reed, Cheryl AM
Willey, James C
author_facet Harr, Michael W
Graves, Timothy G
Crawford, Erin L
Warner, Kristy A
Reed, Cheryl AM
Willey, James C
author_sort Harr, Michael W
collection PubMed
description BACKGROUND: Cell proliferation control depends in part on the carefully ordered regulation of transcription factors. The p53 homolog p73, contributes to this control by directly upregulating the cyclin dependent kinase inhibitor, p21(waf1/cip1). E2F1, an inducer of cell proliferation, directly upregulates p73 and in some systems upregulates p21 directly. Because of its central role in controlling cell proliferation, upregulation of p21 has been explored as a modality for treating bronchogenic carcinoma (BC). Improved understanding of p21 transcriptional regulation will facilitate identification of BC tissues that are responsive to p21-directed therapies. Toward this goal, we investigated the role that E2F1 and p73 each play in the transcriptional regulation of p21. RESULTS: Among BC samples (N = 21) p21 transcript abundance (TA) levels varied over two orders of magnitude with values ranging from 400 to 120,000 (in units of molecules/10(6 )molecules β-actin). The p21 values in many BC were high compared to those observed in normal bronchial epithelial cells (BEC) (N = 18). Among all BC samples, there was no correlation between E2F1 and p21 TA but there was positive correlation between E2F1 and p73α (p < 0.001) TA. Among BC cell lines with inactivated p53 and wild type p73 (N = 7) there was positive correlation between p73α and p21 TA (p < 0.05). Additionally, in a BC cell line in which both p53 and p73 were inactivated (H1155), E2F1 TA level was high (50,000), but p21 TA level was low (470). Transiently expressed exogenous p73α in the BC cell line Calu-1, was associated with a significant (p < 0.05) 90% increase in p21 TA and a 20% reduction in E2F1 TA. siRNA mediated reduction of p73 TA in the N417 BC cell line was associated with a significant reduction in p21 TA level (p < 0.01). CONCLUSION: p21 TA levels vary considerably among BC patients which may be attributable to 1) genetic alterations in Rb and p53 and 2) variation in TA levels of upstream transcription factors E2F1 and p73. Here we provide evidence that p73 upregulates p21 TA in BC tissues and upregulated p21 TA may result from E2F1 upregulation of p73 but not from E2F1 directly.
format Text
id pubmed-1185562
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-11855622005-08-13 Variation in transcriptional regulation of cyclin dependent kinase inhibitor p21(waf1/cip1 )among human bronchogenic carcinomas Harr, Michael W Graves, Timothy G Crawford, Erin L Warner, Kristy A Reed, Cheryl AM Willey, James C Mol Cancer Research BACKGROUND: Cell proliferation control depends in part on the carefully ordered regulation of transcription factors. The p53 homolog p73, contributes to this control by directly upregulating the cyclin dependent kinase inhibitor, p21(waf1/cip1). E2F1, an inducer of cell proliferation, directly upregulates p73 and in some systems upregulates p21 directly. Because of its central role in controlling cell proliferation, upregulation of p21 has been explored as a modality for treating bronchogenic carcinoma (BC). Improved understanding of p21 transcriptional regulation will facilitate identification of BC tissues that are responsive to p21-directed therapies. Toward this goal, we investigated the role that E2F1 and p73 each play in the transcriptional regulation of p21. RESULTS: Among BC samples (N = 21) p21 transcript abundance (TA) levels varied over two orders of magnitude with values ranging from 400 to 120,000 (in units of molecules/10(6 )molecules β-actin). The p21 values in many BC were high compared to those observed in normal bronchial epithelial cells (BEC) (N = 18). Among all BC samples, there was no correlation between E2F1 and p21 TA but there was positive correlation between E2F1 and p73α (p < 0.001) TA. Among BC cell lines with inactivated p53 and wild type p73 (N = 7) there was positive correlation between p73α and p21 TA (p < 0.05). Additionally, in a BC cell line in which both p53 and p73 were inactivated (H1155), E2F1 TA level was high (50,000), but p21 TA level was low (470). Transiently expressed exogenous p73α in the BC cell line Calu-1, was associated with a significant (p < 0.05) 90% increase in p21 TA and a 20% reduction in E2F1 TA. siRNA mediated reduction of p73 TA in the N417 BC cell line was associated with a significant reduction in p21 TA level (p < 0.01). CONCLUSION: p21 TA levels vary considerably among BC patients which may be attributable to 1) genetic alterations in Rb and p53 and 2) variation in TA levels of upstream transcription factors E2F1 and p73. Here we provide evidence that p73 upregulates p21 TA in BC tissues and upregulated p21 TA may result from E2F1 upregulation of p73 but not from E2F1 directly. BioMed Central 2005-07-13 /pmc/articles/PMC1185562/ /pubmed/16014176 http://dx.doi.org/10.1186/1476-4598-4-23 Text en Copyright © 2005 Harr et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Harr, Michael W
Graves, Timothy G
Crawford, Erin L
Warner, Kristy A
Reed, Cheryl AM
Willey, James C
Variation in transcriptional regulation of cyclin dependent kinase inhibitor p21(waf1/cip1 )among human bronchogenic carcinomas
title Variation in transcriptional regulation of cyclin dependent kinase inhibitor p21(waf1/cip1 )among human bronchogenic carcinomas
title_full Variation in transcriptional regulation of cyclin dependent kinase inhibitor p21(waf1/cip1 )among human bronchogenic carcinomas
title_fullStr Variation in transcriptional regulation of cyclin dependent kinase inhibitor p21(waf1/cip1 )among human bronchogenic carcinomas
title_full_unstemmed Variation in transcriptional regulation of cyclin dependent kinase inhibitor p21(waf1/cip1 )among human bronchogenic carcinomas
title_short Variation in transcriptional regulation of cyclin dependent kinase inhibitor p21(waf1/cip1 )among human bronchogenic carcinomas
title_sort variation in transcriptional regulation of cyclin dependent kinase inhibitor p21(waf1/cip1 )among human bronchogenic carcinomas
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1185562/
https://www.ncbi.nlm.nih.gov/pubmed/16014176
http://dx.doi.org/10.1186/1476-4598-4-23
work_keys_str_mv AT harrmichaelw variationintranscriptionalregulationofcyclindependentkinaseinhibitorp21waf1cip1amonghumanbronchogeniccarcinomas
AT gravestimothyg variationintranscriptionalregulationofcyclindependentkinaseinhibitorp21waf1cip1amonghumanbronchogeniccarcinomas
AT crawforderinl variationintranscriptionalregulationofcyclindependentkinaseinhibitorp21waf1cip1amonghumanbronchogeniccarcinomas
AT warnerkristya variationintranscriptionalregulationofcyclindependentkinaseinhibitorp21waf1cip1amonghumanbronchogeniccarcinomas
AT reedcherylam variationintranscriptionalregulationofcyclindependentkinaseinhibitorp21waf1cip1amonghumanbronchogeniccarcinomas
AT willeyjamesc variationintranscriptionalregulationofcyclindependentkinaseinhibitorp21waf1cip1amonghumanbronchogeniccarcinomas